Akums Drugs And Pharmaceuticals share price
You have to be logged in to add this to Watchlist.- ₹500.45(-1.04%)March 21, 2025 15:47:08 PM IST
- NSE
- BSE
- Vol : 996.87K (NSE + BSE)Last 20 day avg : 394.60 K
Akums Drugs And Pharmaceuticals is trading -1.04% lower at Rs 500.45 as compared to its last closing price. Akums Drugs And Pharmaceuticals has been trading in the price range of 524.45 & 490.90. Akums Drugs And Pharmaceuticals has given -21.61% in this year & -1.92% in the last 5 days. The company posted a net profit of 65.18 Crores in its last quarter.Listed peers of Akums Drugs And Pharmaceuticals include Gmr Power And Urban Infra (2.78%), Happy Forgings (4.79%), Akums Drugs And Pharmaceuticals (-1.04%).The Mutual Fund holding in Akums Drugs And Pharmaceuticals was at 5.54% in 31 Dec 2024. The MF holding has increased from the last quarter. The FII holding in Akums Drugs And Pharmaceuticals was at 6.36% in 31 Dec 2024. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Mar 23, 2025, 01:22 AM UTC
- P/B11.10The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values0.00Price-to-earnings ratio based on trailing 12-month earnings
- Debt To EquityHigher than industry0.80The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend Yield-Annual dividends as a percentage of the stock price.
- Beta-Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is not profitable
Company has registered a profit of 65.18 cr vs a loss of 156.42 cr in the same quarter last year.- The debt to equity of the company is higher than the industry median
- R1
- 511.18
- R2
- 567.37
- R3
- 606.08
- S1
- 416.28
- S2
- 377.57
- S3
- 321.38
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Gmr Power And Urban Infra | NA | 111.15 | 2.78 | 7,945.45 | - | - | - | |
| Happy Forgings | Neutral | 837.10 | 4.79 | 7,854.08 | 30.80 | 4.82 | 0.49 | - |
| Akums Drugs And Pharmaceuticals | Bearish | 500.45 | -1.04 | 7,876.78 | 605.75 | 11.1 | - | 20.61 |
| Zinka Logistics Solutions | Bearish | 409.00 | 0.11 | 7,234.90 | - | 23.28 | - | 3.41 |
| P N Gadgil Jewellers | Neutral | 533.75 | 0.69 | 7,243.43 | 47.01 | 13.55 | - | 25.76 |
- Promoter(s) holds a high stake in the company at 75.26%
- FIIs are invested in this company
- FIIs holding has decreased by 0.98 percentage points from previous quarter
- Mutual Funds holding has increased by 0.36 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-02-06 | Quarterly Results |
| 2024-11-09 | Quarterly Results |
| 2024-08-24 | Quarterly Results |
- Industry
- ISININE09XN01023
- BSE Code144222
- NSE CodeAKUMS
Akums Drugs And Pharmaceuticals is trading at 500.45 as on Fri Mar 21 2025 10:17:08. This is -1.04% lower as compared to its previous closing price of 505.70.
The market capitalization of Akums Drugs And Pharmaceuticals is 7876.78 Cr as on Fri Mar 21 2025 10:17:08.
The 52 wk high for Akums Drugs And Pharmaceuticals is 1175.90 whereas the 52 wk low is 432.60
Akums Drugs And Pharmaceuticals can be analyzed on the following key metrics -
- TTM P/E:
- Sector P/E: 38.35
- Dividend Yield: %
- D/E ratio: -
Akums Drugs And Pharmaceuticals reported a net profit of -4.04 Cr in 2024.
The Mutual Fund Shareholding was 5.54% at the end of 31 Dec 2024.